Chris Kilbee Appointed Group Director of UBM Pharma Portfolio

CPhI, part of UBM Live, has announced the appointment of Chris Kilbee to the role of Group Director of the UBM Pharma Portfolio. Central to the role is responsibility for the strategic development and delivery of market leading event brands CPhI, ICSE, Inno-Pack and P-MEC, held in Europe, China, India, Japan, Russia, Turkey, South America and South-East Asia and digital solutions including CPhI Online and CPhI Pharma Evolution.

Chris will be responsible for the delivery of trusted CPhI global brands that connect Pharma buyers and suppliers, a continued focus on providing high-quality content and conferences, and added value for customers. He has targeted growth in emerging markets, mirroring shifts within the wider pharma industry, with CPhI continuing to expand into the world’s largest and growing markets.

Chris has already overseen the launch of CPhI Istanbul - a new event starting in 2014 - and the completion of the company’s first Annual Industry Report.

Utilizing a newly formed expert industry panel, the report featured an unbiased analysis of the global pharmaceutical market, holistically examining the current environment and forecasting future trends.

A highly experienced business leader who has worked across a number of different parts of UBM, most recently running a media and events business based in London Chris brings new insights and approaches to the pharma brand.

Commenting on his appointment, Kilbee remarked: “I am delighted to be taking on this position and overseeing the Pharma portfolio at UBM Live. It is our vision to widen CPhI’s pharma portfolio across new and diverse geographies and platforms where we see opportunities emerging, delivering new services that help to connect the pharma community. CPhI has a proven record of delivery built over two decades and we continually strive to evolve the business so that it remains flexible and adapts alongside the global pharma market- maintaining and expanding the brand’s reach as the essential hub to meet new contacts and build partnerships.”

He continued: “This year we will launch CPhI in Istanbul and we want to continue focusing on leading the development of the brand within markets where there are significant opportunities for growth in exports, and/or burgeoning domestic markets with modernizing healthcare reimbursement models. This will ensure CPhI helps international pharma executives and manufacturers to develop the new pharma economies globally”.

RELATED ARTICLES

Proteins and their behaviour are crucial to understanding how diseases develop, identifying the way that drugs interact with their targets, and developing new methods for matching the right treatment to the right patient at the right time.

Many life-saving medicines, including insulin, antibodies and vaccines, are derived from living cells. These “biologics” can be difficult to obtain and store on the battlefield or in remote areas. That’s why scientists are trying to develop portable systems that can quickly manufacture small batches of protein therapeutics on demand.